Bill > SB289

This bill modifies Oregon's prescription drug pricing transparency and affordability regulations by making several key changes. The bill requires pharmaceutical manufacturers to report detailed information about prescription drug prices annually to the Department of Consumer and Business Services, including factors contributing to price increases, research and development costs, manufacturing expenses, sales revenue, and patient assistance program details. The Prescription Drug Affordability Board will now review these reports on an annual basis (instead of quarterly) and identify up to nine drugs and at least one insulin product that may create affordability challenges for patients. The board is instructed to consider various criteria when reviewing drug prices, such as potential health inequities, prescription rates, price concessions, and patient access. The bill also prohibits the board from using age or disability-based metrics like quality-adjusted life-years when assessing drug cost-effectiveness, ensuring equal valuation of life quality across patient populations. Additionally, the board must now include a report on the generic drug market status in its annual report to legislative health committees, examining aspects like generic drug prices, insurance premium impacts, potential shortages, and spending effects. These changes aim to increase transparency in prescription drug pricing and help address affordability concerns for Oregon residents.

Health and Social Services

https://olis.oregonlegislature.gov/liz/2025R1/Measures/Overview/SB289